Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-485-8 | CAS number: 822-06-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
In a guinea pig maximization test (GPMT) similar to OECD TG 406 1,6-hexamethylene diisocyanate (HDI) revealed a strong skin sensitizing potential. At the topical challenges (4 and 6 weeks after the first induction treatment) 16/17 or 17/17 animals reacted with erythema according to a contact allergy after application of a 0.3 or a 1.0 % HDI formulation in petrolatum (Schmidt and Bomhard, 1983). A Buehler test in guinea pigs showed a strong skin sensitizing potential of HDI (1 % induction conc., 70 % incidence of sensitization) according to EU method B.6 (Zissu et al., 1998). In a mouse local lymph node assay (LLNA) equivalent to OECD TG 429 HDI revealed a clear skin sensitizing potential (Hilton et al., 1995). In addition, HDI was found to be positive in mice using the mouse ear swelling test (MEST; Gad et al., 1986; Thorne et al., 1987). In summary, HDI was found to induce dermal sensitization in animals.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
A lung sensitization test in guinea pigs provides clear evidence that 1,6-hexamethylene diisocyanate (HDI) is a respiratory sensitizer. When animals that were sensitized intradermally (three injections, one per day) or by inhalation (5 x 3 hours per day) and were subsequently challenged by inhalation with the respective hapten of HDI no conclusive immediate-onset responses were observed. As a result of challenge with the respective conjugate of the hapten conclusive immediate-onset responses occurred. Additional evidence of a lung sensitizing potential was provided by the histopathological examination which revealed an increased eosinophilia of airways and lung associated lymph nodes as well as specific IgG1-antibody (Pauluhn, 1996). In a modified local lymph node assay (LLNA) on male mice high stimulation indices (SIs) were observed in mandibular lymph nodes (SI = 9.8) and in auricular lymph nodes (SI = 109) after 6-hour vapour inhalation of 7.5 mg/m3 for three consecutive days. HDI inhalation induced positive responses of IL-4 and IL-10 in the mandibular lymph nodes, whereas for IL-12 and IFN-gamma no dose-response in mandibular lymph nodes was found (Arts et al., 2008; De Jong et al., 2009). In summary, HDI was found to induce respiratory sensitization in animals.
In a further study 1,6-hexamethylene diisocyanate (HDI) was investigated in skin-sensitized Brown Norway (BN) rats for its concentration x time (Cxt)-response relationship on elicitation-based endpoints (Kopf, 2015a). The major goal of the study was to determine the elicitation inhalation threshold dose in sensitized, re-challenged BN rats, including the associated variables affecting the dosimetry of inhaled HDI-vapor in rats. After topical induction (2% HDI on days 0 and 7) most of the rats showed slight to moderate signs of local reactions (application site reddened with red encrustations, and inflammation), especially after the second booster administration. The local reactions waned to an appreciable extent within 1 week after the last dosing. After each challenge exposure mild and transient signs of upper respiratory tract irritation were observed in equally challenged naive and sensitized rats. Body weights were indistinguishable between the groups. Only a slight tendency of decreased body weights occurred in group 4a (124-89-74 mg/m3 for 30 min. and 72 mg/m3 for 6 min.). Delayed-type respiratory measurements did demonstrate changes in respiratory patterns after the last challenge. Two HDI-sensitized rats challenged with 68 mg/m3 x 13 min displayed unusual respiratory responses during the course of measurements. One of these rats succumbed overnight. Lung weights were minimally increased in HDI-induced / challenged rats. NO in exhaled air was mildly increased at the fourth challenge only. Neutrophilic granulocytes (PMNs) in bronchoalveolar lavage fluid (BAL) were considered as the endpoint of choice to integrate the allergic pulmonary inflammation. In summary, Cxt-dependent increased PMNs in BAL were apparent when employing both the single and repeated challenge protocol. Isolated changes in lung function delayed in onset occurred especially at the longer challenge durations. The isolated reactions seen in two rats challenged for 13 min were not complemented by any other endpoint nor was any challenge-dose related outcome apparent. BAL-PMN was amongst the most sensitive endpoints to probe for respiratory allergy. Based on this most sensitive endpoint showing a clear Cxt-dose-related increase in PMNs 68 mg HDI/m3 x 13 min is considered to be the NOAEL of the study. Hence, based on this endpoint, approx. 900 mg HDI/m3 x min is considered to be the effect threshold for elicitation in sensitized, i.e. asthmatic rats.
Justification for classification or non-classification
Skin sensitisation
According to Regulation (EC) No 1272/2008, Annex VI, classified as skin sensitising Cat.1 (H317: May cause an allergic skin reaction).
Respiratory sensitisation
According to Regulation (EC) No 1272/2008, Annex VI, classified as respiratory sensitising Cat.1 (H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.